Sage Journals: Discover world-class research

Abstract

Poly(ADP-ribose) (PAR) is a polymer synthesized by poly(ADP-ribose) polymerases (PARPs) and metabolized into free adenosine diphosphate (ADP)-ribose units by poly(ADP-ribose) glycohydrolase (PARG). Perturbations in PAR synthesis have been shown to play a key role in brain disorders including postischemic brain damage. A single parg gene but two PARG isoforms (110 and 60 kDa) have been detected in mouse cells. Complete suppression of parg gene causes early embryonic lethality, whereas mice selectively lacking the 110 kDa PARG isoform (PARG^−/−₁₁₀) develop normally. We used PARG^−/−₁₁₀ mice to evaluate the importance of PAR catabolism to postischemic brain damage. Poly(ADP-ribose) contents were higher in the brain tissue of PARG^−/−₁₁₀ than PARG^+/+₁₁₀ mice, both under basal conditions and after PARP activation. Distal middle cerebral artery occlusion caused higher increase of brain PAR levels and larger infarct volumes in PARG^−/−₁₁₀ mice than in wild-type counterparts. Of note, the brain of PARG^−/−₁₁₀ mice showed reduced heat-shock protein (HSP)-70 and increased cyclooxygenase-2 expression under both control and ischemic conditions. No differences were detected in brain expression/activation of procaspase-3, PARP-1, Akt, HSP-25 and interleukin-1β. Our findings show that PAR accumulation worsens ischemic brain injury, and highlight the therapeutic potential of strategies capable of maintaining PAR homeostasis.

Keywords

cyclooxygenase heat-shock proteins ischemic stroke poly(ADP-ribose)

Introduction

Poly(ADP-ribose) polymerases (PARPs) are nicotinamide adenine dinucleotide (NAD)-consuming enzymes forming poly(ADP-ribose) (PAR) and involved in maintenance of nuclear homeostasis. Among them, the DNA damage-activated PARP-1 shows the highest poly(ADP-ribosyl)ating activity. Poly(ADP-ribose) consists of long, branched and negatively charged polymers of ADP-ribose units whose polymerization onto chromatin-interacting proteins including PARP-1 significantly affects their functioning through electric repulsion and steric hindrance (D'Amours et al, 1999; Smith, 2001; Herceg and Wang, 2001). A large body of evidence shows that PAR formation increases during brain ischemia and participates in stroke pathogenesis (for a review see Chiarugi, 2005b). Several mechanisms can underlie the neurotoxic role of PAR in ischemic brain injury (Chiarugi, 2005a). For instance, bulk PAR neoformation causes NAD depletion that in turn prompts adenosine triphosphate (ATP) depletion and cellular energy failure (Szabo and Dawson, 1998; Ha and Snyder, 2000; Skaper, 2003). In addition, PAR can trigger mitochondrial release of apoptosis-inducing factor (AIF) and ensuing neuronal death (Hong et al, 2004). Finally, a key role for PAR in transcription of genes involved in neurotoxicity/neuroprotection has been reported (Ullrich et al, 2001; Chiarugi, 2002; Ha et al, 2002; Chiarugi and Moskowitz, 2003; Park et al, 2004). However, despite remarkable neuroprotection conferred by suppression of PAR neosynthesis during brain ischemia, underlying mechanisms still wait to be clearly established (Moroni et al, 2001; Chiarugi, 2002; Goto et al, 2002). Intriguingly, ischemic neuroprotection by PARP-1 suppression in the mouse seems to be restricted to males (Hagberg et al, 2004; McCullough et al, 2005).

In contrast with the increasing number of PARPs involved in poly(ADP-ribosyl)ation (Ame et al, 2004), poly(ADP-ribose) glycohydrolase (PARG) is the only enzyme capable of degrading PAR into ADP-ribose identified so far (Davidovich et al, 2001; Bonicalzi et al, 2005). Poly(ADP-ribose) glycohydrolase is ubiquitously expressed in mammalian cells and cleaves PAR into free ADP-ribose units owing to its exoglycosidic activity. Nuclear localization and exportation signals in PARG amino-acid sequence allow its nucleocytoplasmic shuttling and efficient PAR catabolism (Bonicalzi et al, 2003). Although little is known about the pathophysiologic role of PARG, its involvement in cell cycle regulation (Ohashi et al, 2003), mitotic spindle assembly (Chang et al, 2004), development (Hanai et al, 2004; Koh et al, 2004), differentiation (Di Meglio et al, 2003), and cell death (Affar et al, 2001; Ying et al, 2001; Hanai et al, 2004) has been reported.

Given the cytotoxic potential of PAR, attention has been devoted to elucidating the role of PARG in disease pathogenesis. The complete suppression of the parg gene causes early embryonic lethality (Koh et al, 2004), thereby precluding studies in adult animals. Conversely, the recently developed mice selectively lacking the 110 kDa isoform of PARG (PARG^−/−₁₁₀) are viable and apparently develop normally, despite being more susceptible to genotoxic shock and endotoxin treatment (Cortes et al, 2004). To further understand the role of PARG in the brain and its relevance to stroke pathogenesis, in this study we investigated basal and ischemia-induced cerebral PAR contents as well as sensitivity to ischemic brain injury in PARG^−/−₁₁₀ mice. In these animals, we also evaluated constitutive and ischemia-induced brain expression of several neuroprotective or neurotoxic proteins, as well as the extent of PARP-1-dependent brain energy derangement.

Materials and methods

Induction of Distal Middle Cerebral Artery Occlusion and Determination of Infarct Size

Development and genotyping of PARG^−/−₁₁₀ mice has been reported previously (Cortes et al, 2004). In this study, we used homozygous knockout and wild-type mice. They derived originally from heterozygous intercrosses (i.e., heterozygous PARG₁₁₀ mice with a 129/Sv/Ola background were intercrossed and homozygous mice were then kept in sister–brother breeding for five generations). Permanent distal middle cerebral artery occlusion (MCAO) was induced in age-matched male PARG^−/−₁₁₀ mice and corresponding wild-type littermates (n = 8, per group). Animals (25 to 30 g) were anesthetized with 4% isoflurane and maintained on 1.5% isoflurane in air. Rectal temperature was monitored and maintained between 36.5 and 37.5°C with a homeothermic blanket. A 1 cm vertical scalp incision was made between the right eye and ear. The temporalis muscle was bisected and a 2 mm burr hole was made at the junction of the zygomatic arch and squamous bone. The distal MCA was exposed and permanently occluded by cauterization above the rhinal fissure. Physiologic parameters such as rectal temperature, mean arterial blood pressure and pH, PaO₂ as well as PaCO₂ did not differ between strains before, during, and 1 h after ischemia. After surgery, mice were kept at 37°C for 1 h in an incubator and then placed in their cage until being killed. Mice were killed 14 h (Western blotting and immunohistochemistry) or 24 h (infarct determination) after MCAO, and their brains snap frozen in N₂ vapor for cryostat sectioning. For infarct determination, hematoxylin- and eosin-stained coronal sections (15 μm) were imaged by using the Image 3.0 ProPlus analysis software. Infarct areas were calculated subtracting the area of intact tissue in the ipsilateral hemisphere from the area of the contralateral hemisphere to minimize the error that is introduced by edema, which distorts and enlarges the infarcted tissue and surrounding white matter. Infarct volumes were calculated multiplying the infarct area by the distance among sections as described previously (Swanson and Sharp, 1994).

Western Blotting and Immunohistochemistry

The ischemic and controlateral healthy cortex of mice subjected to 14 h MCAO as well as control and methyl-N-nitroso guanidine (MNNG)-exposed brain slices were collected in eppendorf tubes and stored at −80°C. Samples were homogenized in lysis buffer (50 mmol/L Tris, pH 7.4, 1 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, 4 μg/mL aprotinin and leupeptin, 1% sodium dodecyl sulfate (SDS)), proteins were isolated and measured according to standard techniques, and 20 to 40 μg of protein/lane were loaded. After 4% to 20% SDS-polyacrylamide gel electrophoresis (PAGE) and blotting, membranes (Hybond-ECL, Amersham, UK) were blocked with phosphate-buffered saline (PBS) containing 0.1% Tween-20 and 5% skimmed milk (TPBS/5% milk) and then probed overnight with primary antibodies (1:1000 in TPBS/5% milk). The anti-PAR monoclonal antibody (10H) was from Alexis (Vinci, Italy), the anti-inducible nitric oxide synthase (iNOS) and anti-interleukin (IL)-1β were polyclonal antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and the anti-cyclooxygenase-2 (COX-2) polyclonal antibody was from Cayman Chemicals (Ann Arbor, MI, USA). Membranes were then washed with TPBS and incubated 1 h in TPBS/5% milk containing the corresponding peroxidase-conjugated secondary antibody (1:2000). After washing in TPBS, enhanced chemiluminescence (Amersham, UK) was used to visualize the peroxidase-coated bands. Densitometric data were obtained using the NIH image analysis system (Bethesda, MD, USA) and expressed as the mean ± standard error of mean (s.e.m.). For immunohistochemistry, frozen brains of PARG^+/+₁₁₀ and PARG^−/−₁₁₀ mice subjected to 14 h MCAO were cut with a cryostat, sections mounted on slides, and ethanol-fixed. Slides were preincubated 1 h with PBS/Triton X-100 0.3% (PBST) containing 20 mg/mL bovine serum albumin (BSA) and then overnight with the above-mentioned anti-PAR monoclonal antibody (1:100 in PBST/5 mg/mL BSA). A subsequent incubation (1 h) with a Cy2-conjugated anti-mouse secondary antibody (1:200 in PBST/5 mg/mL BSA) allowed visualization of the binding. A subsequent incubation (2 h) with the anti-neuronal nuclei monoclonal antibody (NeuN) (Chemicon, Tamecula, CA, USA) or anti-glial fibrillary acidic protein (GFAP) (Sigma, Saint Louis, MO, USA) antibodies was performed for double labeling. Binding was revealed with the corresponding Cy3-conjugated secondary antibodies and an inverted Nikon fluorescence microscope. Specificity of immune detection was established by omission of the primary antibody.

Semiquantitative Real-Time Polymerase Chain Reaction

Total RNA (1 μg) extracted from the brain parietal cortex was reverse transcribed and the DNA mixture subjected to polymerase chain reaction (PCR) using the following oligonucleotide primers: PARG₁₁₀, 5′-CCACCTCGTTTGT TTTCA-3′ (sense) and 5′-CCAACATCTGGCAAAGGA-3′ (antisense); PARG₆₀, 5′-GGACCTCCTCTCAAAGAGACA-3′ (sense) and 5′-CTGGGGAAAAAAGGACGAAA-3′ (antisense); and β-actin, 5′-GACCTGACAGACTACCTC-3′ (sense) and 5′-AGACAGCACTGTGTTGGC-3′ (antisense). Numbers of cycles (94°C 30 secs, 58°C 30 secs, 72°C 1 min for PARG₆₀; 94°C 30 secs, 52°C 30 secs, 72°C 1 min for PARG₁₁₀ and β-actin) selected after determining the linear working range for the reaction were 25, 27, 30, and 33 for PARG isoforms and 20 for β-actin. PCR products were separated on 1.8% agarose gels.

Measurement of Nicotinamide Adenine Dinucleotide, Adenosine Triphosphate and Adenosine Diphosphate-Ribose in Mouse Brain Slices

Poly(ADP-ribose) glycohydrolase^+/+₁₁₀ and PARG^−/−₁₁₀ mice were anesthetized with isofluorane and decapitated. The cerebellum was removed and brains were immersed in ice-cold PBS and cut with a vibratome to obtain coronal slices of 200 μm. Only coronal sections containing both the cortex and striatum were used, whereas those corresponding to the anterior or posterior regions of the brain were discarded. Slices were preincubated for 1 h in a 24-multiwell plate containing 200 μL of serum-free Dulbecco's modified Eagle's medium (DMEM), at 37°C in a water-saturated 5% CO₂/95% air atmosphere, and then exposed to 1 mmol/L MNNG (directly dissolved in DMEM) for different times. As for NAD measurement, slices were transferred in eppendorf tubes containing 100 μL HClO₄ 1 N, sonicated, and the solution neutralized with an equal volume of KOH 1 N. After the addition of 200 μL bicine 100 mmol/L (pH 8) and centrifugation (13,000g/3 mins), 100 μL of the extract was mixed with an equal volume of bicine buffer containing 23 μL/mL ethanol, 0.17 mg/mL 3-[4,5-dimethylthiazol-2-yl]-2,5-di-phenyltetrazolium bromide (MTT), 0.57 mg/mL fenazine ethosulfate, and 10 μg alcohol dehydrogenase. The mixture was kept at room temperature for 20 mins and then absorbance at 550 nm measured. A standard curve allowed quantification of NAD. Adenosine triphosphate was measured in 50 μL of the neutralized slice extract by means of the ATPlite luminescence detection kit (Perkin-Elmer, Zaventem, Belgium). Adenosine diphosphate-ribose was quantified by high-performance liquid chromatography (HPLC) and ultraviolet (UV) detection kit (Perkin-Elmer model LC 90). Briefly, MNNG-treated slices were transferred in eppendorf tubes containing 100 μL HClO₄ (50 mmol/L), sonicated, boiled, and neutralized with 100 μL KOH (50 mmol/L). The extract was centrifuged (12,000 g/5 mins) and 100 μL of the supernatant injected in a C18 5 μm, 4.6 × 250 mm, Nucleosil HPLC column. The mobile phase was 100 mmol/L phosphate buffer, pH 7.5, containing 13 mmol/L tetrabutylammonium bromide and 1% acetonitrile at 1 mL/min flow rate. Absorbance was measured at 260 nm.

Results

Transcription of Poly(ADP-Ribose) Glycohydrolase Isoforms in Poly(ADP-Ribose) Glycohydrolase₁₁₀ Wild-Type and Knockout Mouse Brains

Although a single parg gene is present in mouse genome, mouse embryonic fibroblasts express two PARG isoforms of 110 and 60 kDa because of the presence of an alternative translation start codon in exon 4 (Figure 1A). Consistently, deletion of exons 2 and 3 in parg gene generates mouse lacking PARG₁₁₀ but still expressing PARG₆₀ (Cortes et al, 2004). To investigate whether transcription of PARG₆₀ also occurs in the brain of adult PARG^−/−₁₁₀ mice, we used complementary deoxyribonucleic acid (cDNA) derived from the brain cortex of wild-type and knock out animals and forward and reverse primers amplifying sequences in exon 2 or 13 of parg. Both couples of primers amplified sequences of the predicted molecular weight in cDNA deriving from PARG^+/+₁₁₀ brain cortex. Conversely, only primers binding to exon 13 gave an amplification product when cDNA from PARG^−/−₁₁₀ mouse cortex was used (Figure 1Ba), suggesting that PARG₆₀ was expressed in the brain of PARG^−/−₁₁₀ mice. In principle, disruption of exons 2 and 3 in PARG gene might favor transcription of PARG₆₀. Given that anti-PARG antibodies are not currently available, we compared the amount of amplification products of exon 13 (obtained with different number of cycles comprised in the linear working range of the reaction to warrant semiquantitative analysis) by using cDNA from the cortex of PARG^+/+₁₁₀ and PARG^−/−₁₁₀ mice. As shown in Figure 1Bb, the amount of amplification products did not differ between strains, suggesting that PARG₆₀ expression is not altered in PARG₁₁₀ null mice.

Figure 1

Transcription of poly(ADP-ribose) glycohydrolase (PARG) isoforms in the mouse brain. (A) Schematic representation of PARG complementary deoxyribonucleic acid (cDNA) exons (gray rectangles) of PARG₁₁₀ wild-type and knock out mice. In wild-type mice, translation starting at ATG on exon 1 or 4 leads to PARG isoforms of 110 or 60 kDa, respectively. In knockout animals, deletion of exons 2 and 3 selectively abolishes translation of PARG₁₁₀ (Ba) Poly(ADP-ribose) glycohydrolase₁₁₀ and PARG₆₀ transcripts are both present in the cortex of wild-type mice, whereas only those for PARG₆₀ are detected in the brain of PARG^−/−₁₁₀ animals. (Bb) Semiquantitative analysis of PARG₁₁₀ and PARG₆₀ transcripts obtained with different numbers of PCR cycles comprised in the linear working range of the reaction shows that mRNA levels of PARG₆₀ do not differ in the cortex of PARG^+/+₁₁₀ and PARG^−/−₁₁₀ mice. In (B), one experiment representative of three is shown.

Effect of Poly(ADP-Ribose) Glycohydrolase₁₁₀ Deletion on the Brain Tissue Response to Poly(ADP-Ribose) Polymerase-1 Hyperactivation

To study the effects of PARG₁₁₀ deletion on brain PAR levels and energy dynamics, we evaluated PAR, NAD, ATP, and ADP-ribose contents in brain slices (50 μm) of PARG^−/−₁₁₀ and PARG^+/+₁₁₀ mice under basal conditions or after exposure to MNNG, a widely used PARP-1 activator (Ha and Snyder, 1999; Yu et al, 2002). Although it is possible that both constitutive PARP-1 activity and polymer contents are altered during slice preparation, Figure 2Aa shows that basal PAR level was higher in PARG^−/−₁₁₀ than in PARG^+/+₁₁₀ brain slices. MNNG exposure caused a rapid (5 mins) and transient (30 mins duration) increase of PAR content in both wild-type and PARG^−/−₁₁₀ brain tissue. At each time point after MNNG exposure, brain slices obtained from PARG^−/−₁₁₀ mice had higher PAR contents than those obtained from PARG^+/+₁₁₀ animals (Figure 2Ab). Basal NAD contents were 5.9 ± 1.1 and 7.4 ± 0.9 nmol/mg protein in PARG^+/+₁₁₀ and PARG^−/−₁₁₀ brain slices, respectively, and were not significantly affected by MNNG exposure (Figure 2Ba). Basal ATP levels were 16.6 ± 2.3 and 18.3 ± 3 nmol/mg protein in PARG^+/+₁₁₀ and PARG^−/−₁₁₀ brain slices, respectively. Adenosine triphosphate contents decreased to about 55% at 15 and 30 mins after MNNG exposure in slices from both mouse strains (Figure 2Bb). The basal ADP-ribose contents were 5.6 ± 1.3 and 6.2 ± 0.4 nmol/mg protein in PARG^+/+₁₁₀ and PARG^−/−₁₁₀ brain slices, respectively. On exposure to MNNG, ADP-ribose contents increased equally (analysis of variance + Tukey's post hoc test) and time-dependently in PARG^+/+₁₁₀ and PARG^−/−₁₁₀ slices (Figure 2Bc).

Figure 2

Effect of methyl-N-nitroso guanidine (MNNG) on contents of poly(ADP-ribose) (PAR), adenosine triphosphate (ATP) and adenosine diphosphate (ADP)-ribose in brain slices of poly(ADP-ribose) glycohydrolase (PARG)^+/+₁₁₀ and PARG^−/−₁₁₀ mice. (Aa) Exposure to MNNG (1 mmol/L) prompts rapid (5 mins) increase of PAR contents in brain slices (50 μm) from PARG^+/+₁₁₀ animals. (Ab) Densitometric analysis reveals that PAR contents are higher in PARG^−/−₁₁₀ than in PARG^+/+₁₁₀ slices under control conditions as well as after MNNG exposure. Note that contents of PAR started to decrease in both PARG^+/+₁₁₀ and PARG^−/−₁₁₀ slices 30 mins after MNNG challenge. (Ba) Exposure to MNNG has no effect on nicotinamide adenine dinucleotide (NAD) contents, whereas (Bb) reduces ATP contents in brain slices of both mouse strains with a comparable time course and to a similar level. (Bc) Methyl-N-nitroso guanidine exposure causes an equal (analysis of variance + Tukey's post hoc test) and time-dependent increase of ADP-ribose content in PARG^+/+₁₁₀ and PARG^−/−₁₁₀ brain slices. In (A), one blot representative of three is shown. β-Actin is shown as loading control. In (Ba–c), each point represents the mean ± standard error of mean (s.e.m.) of three experiments conducted in duplicate.

Poly(ADP-ribose) Glycohydrolase₁₁₀ Deletion Increases the Vulnerability to Ischemic Brain Injury

The finding that PAR accumulated in the brain tissue of PARG^−/−₁₁₀ mice, along with the relevance of the polymer to stroke pathogenesis, prompted us to evaluate the sensitivity of these animals to the ischemic brain injury. In line with lack of phenotype or developmental abnormalities in PARG^−/−₁₁₀ animals (Cortes et al, 2004), there were no macroscopic differences in size and histology (hematoxylin/eosin staining) between PARG^+/+₁₁₀ and PARG^−/−₁₁₀ mouse brains (Figure 3C and not shown). To investigate whether PARG₁₁₀ plays a role in brain ischemic injury, PARG^+/+₁₁₀ and PARG^−/−₁₁₀ mice were subjected to distal MCAO. Rectal temperature, mean arterial blood pressure, pH, PaO₂, and PaCO₂ did not differ between strains before, during, and 1 h after ischemia (not shown). Twenty-four hours after MCAO, PARG^−/−₁₁₀ mice had a larger infarct volume than wild-type animals (11.8 ± 1.3 versus 6.7 ± 1 mm³, respectively; n = 8 per group; *P < 0.05, **P < 0.01, Student's t-test; Figure 3A). In keeping with the ischemic model we used, most of the infarct was in the cortex. The striatum was minimally injured in two out of eight wild-type and three out of eight PARG^−/−₁₁₀ mice (Figures 3A to C).

Figure 3

Deletion of poly(ADP-ribose) glycohydrolase(PARG)₁₁₀ worsens ischemic brain injury. Infarct volumes (A) and infarct areas (B) in the brain of mice subjected for 24 h to distal middle cerebral artery occlusion (MCAO) in PARG^−/−₁₁₀ mice and in wild-type littermates. (C) Visualization of hematoxylin- and eosin-stained brain sections (15 μm) from PARG^+/+₁₁₀ and PARG^−/−₁₁₀ animals 24 h after MCAO. *P < 0.05, **P < 0.01 versus infarct volume or corresponding infarct areas of PARG^+/+₁₁₀ mice (Student's t-test), n = 8/group.

Poly(ADP-Ribose) Glycohydrolase₁₁₀ Deletion Increases Basal and Ischemia-Induced Cerebral PAR Contents

Figure 4 shows that PAR contents in the brain cortex were higher in PARG^−/−₁₁₀ than wild-type animals both under basal conditions and after MCAO. The figure also shows that the pattern of poly(ADP-ribosyl)ated proteins in the two mouse strains consisted of a smear of 200 to 140 kDa, plus strong (∼58 and 25 kDa) and faint (∼15, 36, and 110 kDa) bands. Size and density of the 58, 25, and 15 kDa bands increased in the ischemic cortex of both strains. Densities of the 110 and 36 kDa bands (classically related to PARP-1 and histone H1, respectively; D'Amours et al, 1999; Rouleau et al, 2004) were not consistently increased in ischemic tissues.

Figure 4

Poly(ADP-ribose) (PAR) contents in the cortex obtained from control (controlateral) and ischemic sites of poly(ADP-ribose) glycohydrolase (PARG)^+/+₁₁₀ and PARG^−/−₁₁₀ mice. (A) Poly(ADP-ribosyl)ated proteins distribute in smeared (200 to 140 kDa) as well as in large (∼58 and 25 kDa) and faint (∼15, 36, and 110 kDa) bands in the controlateral cortex (C) of PARG^+/+₁₁₀ and PARG^−/−₁₁₀ mice subjected to 14 h MCAO. Poly(ADP-ribose) contents increase in the ischemic cortex (Is) of both mouse strains. A blot representative of three, each with two animals per group is shown. β-Actin is shown as loading control. (B) Densitometric analysis reveals that levels of PAR in the controlateral and ischemic cortex of PARG^−/−₁₁₀ mice are higher than those present in the corresponding cortex of PARG^+/+₁₁₀ animals.

In the controlateral cortex of PARG^+/+₁₁₀ mice, immunoreactivity of PAR was weak and homogeneously scattered, whereas some densely stained cells were present in the peri-infarct zone (Figure 5A). In keeping with Western blotting, PAR immunoreactivity was higher in the controlateral cortex of PARG^−/−₁₁₀ mice compared with that of PARG^+/+₁₁₀ animals. Of note, numerous densely stained cells were found in the peri-infarct area of PARG^−/−₁₁₀ mouse brains (Figure 5A). Poly(ADP-ribose) immunoreactivity appeared perinuclear in the controlateral cortex of PARG^+/+₁₁₀ and PARG^−/−₁₁₀ mice. On the contrary, PAR mostly localized in the nucleus of cells in the ischemic cortex of both mouse strains (Figure 5B). Double labeling experiments revealed that these nuclei were positive for the neuronal marker NeuN in the ischemic cortex of both PARG^+/+₁₁₀ and PARG^−/−₁₁₀ mice. Conversely, PAR immunoreactivity was almost completely absent in GFAP-positive astrocytes of the ischemic tissue (Figure 6).

Figure 5

Immunohistochemical visualization of poly(ADP-ribose) (PAR) in control and ischemic cortex of poly(ADP-ribose) glycohydrolase (PARG)^+/+₁₁₀ and PARG^−/−₁₁₀ mice. (A) In the controlateral (Control) cortex of PARG^+/+₁₁₀ mice, PAR immunoreactivity is weak and homogeneously scattered, whereas densely stained cells (arrows) appear in the peri-infarct area (delimited by a dotted line) of the ischemic cortex 14 h after middle cerebral artery occlusion (MCAO). Poly(ADP-ribose) immunoreactivity is stronger in the controlateral cortex of PARG^−/−₁₁₀ mice compared with that of PARG^+/+₁₁₀ animals. Numerous cells highly immunoreactive for PAR (arrows) are present in the ischemic cortex of PARG^−/−₁₁₀ mice 14 h after MCAO. (B) In the control cortex of PARG^+/+₁₁₀ and PARG^−/−₁₁₀ mice, PAR immunoreactivity localizes in the perinuclear zone (arrows) of cell with large nuclei. Conversely, in the ischemic cortex of both mouse strains PAR immunoreactivity mainly localizes in the nucleus (arrowheads) of cell with large nuclei. Bar = 80 μm (A) and 30 μm (B). An experiment representative of three is shown.

Figure 6

Cellular localization of poly(ADP-ribose) (PAR) in the ischemic cortex of poly(ADP-ribose) glycohydrolase (PARG)^+/+₁₁₀ and PARG^−/−₁₁₀ mice 14 h after middle cerebral artery occlusion (MCAO). In the ischemic cortex of wild-type mice, PAR immunoreactivity (green) almost completely colocalizes (yellow, arrows) with neuronal nuclei monoclonal antibody-positive nuclei (red), suggesting neuronal origin. Conversely, sporadic glial fibrillary acidic protein-positive astrocytes (red) have a PAR-positive nucleus (yellow, arrowhead). A similar cellular distribution of PAR is present in the ischemic cortex of PARG^−/−₁₁₀ mice (arrows). One experiment representative of two is shown. Bar = 30 μm.

Effect of Poly(ADP-Ribose) Glycohydrolase₁₁₀ Deletion on Expression/Activation of Neuroprotective or Neurotoxic Proteins in Control and Ischemic Mouse Brain

The brain's gene expression profile plays an important role in postischemic brain damage (Read et al, 2001; Bates et al, 2001; Weinstein et al, 2004; Stenzel-Poore et al, 2004), and PAR finely modulates transcriptional activation (Ziegler and Oei, 2001; Chiarugi, 2002; Kraus and Lis, 2003; Rouleau et al, 2004). On this basis, and also considering that PARG is emerging as a regulator of gene expression (Tsai et al, 1992; Panda et al, 2002; Rapizzi et al, 2004), we compared in PARG^+/+₁₁₀ and PARG^−/−₁₁₀ mice the expression and/or activation profiles of several proteins involved in ischemic brain injury (Figure 7). In the light of the relevance of apoptosis to stroke pathogenesis (Lo et al, 2003) and that of PAR to apoptotic cell death (Hong et al, 2004), we evaluated expression and activation of caspase-3 within the ischemic brain of both mouse strains. Brain expression of procaspase-3 did not differ between PARG^+/+₁₁₀ and PARG^−/−₁₁₀ animals, and reduction of procaspase-3 levels (an index of caspase-3 activation) was similar in the ischemic cortex of both mouse strains (Figure 7A and Ba). Deletion of PARG₁₁₀ did not affect basal expression of PARP-1. Consistent with analogous caspase-3 activation, PARP-1 cleavage (a hallmark of caspase-3 activity) was similar in the ischemic cortex of PARG^+/+₁₁₀ and PARG^−/−₁₁₀ mice. Because Akt phosphorylation promotes neuronal survival and ischemic preconditioning (Datta et al, 1999; Yano et al, 2001), we wondered whether different activation levels of Akt were present in the brain of PARG^−/−₁₁₀ mice. On the contrary, Akt phosphorylation in the controlateral and ischemic cortex did not differ between PARG^+/+₁₁₀ and PARG^−/−₁₁₀ mice. Heat-shock proteins (HSP) participate to ischemic neuroprotection (Weinstein et al, 2004) and are regulated by poly(ADP-ribosyl)ation (Tulin and Spradling, 2003; Zingarelli et al, 2004). Interestingly, HSP-70 expression levels were lower in the controlateral and ischemic cortex of PARG^−/−₁₁₀ mice compared with the corresponding one of wild-type littermates (Figures 7A and Bb). No differences in HSP-25 expression were found between mouse strains under control and ischemic conditions. Finally, considering the relevance of PAR to neuroinflammation (Ullrich et al, 2001; Chiarugi and Moskowitz, 2003; Park et al, 2004), and the pathogenetic role of the inflammatory response to ischemic brain injury (Barone and Feuerstain, 1999; Iadecola and Alexander, 2001), we next evaluated the expression of iNOS, IL-1β, and COX-2 in control and ischemic cortices of PARG^+/+₁₁₀ and PARG^−/−₁₁₀ mice. Importantly, basal and ischemia-induced COX-2 expression was higher in PARG^−/−₁₁₀ compared with PARG^+/+₁₁₀ animals (Figures 7A and Bc). Conversely, iNOS expression was not detected in control or ischemic brain of both animal strains, whereas IL-1β levels in controlateral and ischemic cortex was very weak and did not differ between strains.

Figure 7

Expression of neuroprotective or neurotoxic proteins in control and ischemic brain cortex of poly(ADP-ribose) glycohydrolase (PARG)^+/+₁₁₀ and PARG^−/−₁₁₀ mice 14 h after middle cerebral artery occlusion (MCAO). (A) Basal expression as well as ischemia-induced decrease of procaspase-3 do not differ between strains. Likewise, constitutive expression of poly(ADP-ribose) polymerase (PARP)-1 and its cleavage product after ischemia are not different in PARG^+/+₁₁₀ and PARG^−/−₁₁₀ animals. Akt phosphorylation is neither affected by ischemia nor by PARG₁₁₀ deletion. Levels of heat-shock protein (HSP)-70 but not those of HSP-25 are lower in the control and ischemic cortex of PARG^−/−₁₁₀ mice with respect to wild-type littermates. iNOS was not detected in the control or ischemic cortex of both mouse strains. Interleukin (IL)-1β expression is weak and does not differ between mouse strains under control or ischemic conditions. Constitutive as well as ischemia-induced cyclooxygenase-2 (COX-2) expression is higher in PARG^−/−₁₁₀ compared with PARG^+/+₁₁₀ mice. Representative blots are shown. β-Actin is shown as loading control. (B) Densitometric analysis of procaspase-3, HSP-70 and COX-2 expression in control and ischemic cortex of PARG^+/+₁₁₀ and PARG^−/−₁₁₀ animals. Each column represents the mean ± standard error of mean (s.e.m.) of densitometric values of four different blots.

Discussion

We report here that mice null for PARG₁₁₀ have increased PAR content and increased brain vulnerability to ischemic stroke. These findings provide evidence that PARG activity protects from ischemic brain injury, and point to PAR catabolism as a key determinant of ischemic neurodegeneration.

In eukaryotic cells, several PARG isoforms originating from a single parg gene have been identified (Davidovich et al, 2001). In human cells, alternative splicing of PARG mRNA generates three variants: PARG₁₁₁, PARG₁₀₂, and PARG₉₉ (Meyer-Ficca et al, 2004; Bonicalzi et al, 2005). In mouse cells, alternative transcription initiation of parg gene gives rise to PARG₁₁₀ and PARG₆₀ (see Figure 1A and Cortes et al, 2004 for further details). We show here that transcripts for both PARG₁₁₀ and PARG₆₀ are present in the brain of PARG^+/+₁₁₀ mice, whereas only transcripts for PARG₆₀ are present in cells obtained from PARG^−/−₁₁₀ animals. These findings, along with evidence that ADP-ribose increases on PAR formation in PARG^−/−₁₁₀ brain tissue, suggest that transcripts for PARG₆₀ are translated into a functional PARG in the brain of PARG^−/−₁₁₀ mice. Yet, whether PARG₆₀ in PARG^−/−₁₁₀ mice maintains the same functional properties of PARG₆₀ of wild-type animals requires further investigation. It also waits to be clarified why a ∼3-fold increase of PARG activity has been reported in the mitochondrial fraction of embryonic fibroblasts of PARG^−/−₁₁₀ mice, and PARP-1 auto-poly(ADP-ribosyl)ation levels are reduced in PARG^−/−₁₁₀ cells (Cortes et al, 2004). Together, these events could contribute to the phenotype of mice null for the 110 kDa isoform of PARG.

PAR accumulation and lethality at embryonic day 3.5 in mice with complete inactivation of the parg gene (Koh et al, 2004) indicate an essential role of PARG during mammalian development, and underscore the toxic effects of increased polymer contents. Conversely, PARG^−/−₁₁₀ mice have normal development, suggesting that, under basal condition, PARG₁₁₀ activity is somehow redundant. Poly(ADP-ribose) glycohydrolase₆₀ as well as other putative PAR degrading enzymes such as phosphodiesterases (Davidovich et al, 2001; Rouleau et al, 2004) might partly compensate for lack of PARG₁₁₀. Deletion of PARG₁₁₀, however, does not increase transcript levels for PARG₆₀, suggesting that this type of compensation, if any, is not because of changes in PARG₆₀ expression. However, the observation that basal PAR contents were higher in the brain of PARG^−/−₁₁₀ than wild-type mice implies that PARG₁₁₀ participates in PAR degradation within the brain. Of note, 110 kDa PARG is the dominant PARG isoform normally present in the nucleus. Accordingly, we found that nuclear PAR contents were higher in the ischemic brain of PARG^−/−₁₁₀ than PARG^+/+₁₁₀ mice, suggesting that PARG₁₁₀ is mainly responsible for nuclear PAR degradation on cerebral ischemia. Although nuclear localization of mouse PARG₆₀ has not yet been shown, evidence for a residual PARG activity in the nuclear fraction of PARG^−/−₁₁₀ fibroblasts (Cortes et al, 2004) suggests that PARG₆₀ migrates into the nucleus. This concept is further corroborated by the presence of multiple putative nuclear localization signals codified by sequences downstream to exon 3 in the human PARG gene, and by the notion that significant portions of the PARG sequence are well conserved from rodents to humans (Bonicalzi et al, 2005).

Cerebral PAR contents in PARG^−/−₁₁₀ mice under basal conditions were similar to those induced by ischemia in wild-type animals (Figure 4). Possibly, chronic exposure to high PAR contents in PARG^−/−₁₁₀ mice has lessened the cells' sensitivity to the detrimental effects of polymer accumulation. Accumulation of PAR in the nucleus of PARG^−/−₁₁₀ cortical neurons and their increased vulnerability after ischemia indicate that PARG₁₁₀ is pivotal in maintaining PAR homeostasis in the injured brain. Because PARG-dependent PAR catabolism leads to ADP-ribose, we measured its content in the brain of PARG^+/+₁₁₀ and PARG^−/−₁₁₀ mice. Unexpectedly, we found that ADP-ribose did not differ between the two mouse strains. Considering that ADP-ribose may have a fast enzymatic degradation (Oei and Ziegler, 2000), it is possible that a simple measurement of its steady-state levels is not sufficient to evaluate the rate of its formation.

In keeping with the emerging role of PAR in transcriptional regulation (Ziegler and Oei, 2001; Chiarugi, 2002; Hassa and Hottiger, 2002; Kraus and Lis, 2003; Rouleau et al, 2004), we report here that polymer accumulation in the brain was associated with reduced HSP-70 and increased COX-2 expression. Notably, in line with the present finding that PAR accumulation correlates with decreased levels of HSP-70, the expression of this protein is facilitated in PARP-1^−/– mice (Zingarelli et al, 2004). The augmented expression of COX-2 in the brain of PARG^−/−₁₁₀ mice is in agreement with previous finding showing that these animals are particularly sensitive to septic shock and have higher serum levels of proinflammatory mediators compared with wild-type counterparts after lipopolysaccharide (LPS) challenge (Cortes et al, 2004). Also, it has been recently reported that PARG inhibition causes COX-2 expression (Rapizzi et al, 2004). Notably, reduced expression of HSP-70 in the brain increases vulnerability to ischemic injury (Lee et al, 2001), whereas increased COX-2 activity worsens postischemic brain damage (Barone and Feuerstain, 1999; Iadecola and Alexander, 2001). It is possible therefore that changes in the expression of these two proteins contribute to the increased infarct volume found in PARG^−/−₁₁₀ mice after MCAO. The reduced PARP-1 automodification levels found in PARP-1^−/– mice might have altered the functional properties of PARP-1 as a homeostatic transcriptional regulator, thereby causing transcriptional derangement and increased sensitivity to ischemic brain injury.

A large body of evidence suggests that PARP-1 hyperactivity and PAR formation play a role in postischemic brain damage by triggering NAD/ATP depletion and energy failure (Szabo and Dawson, 1998; Ha and Snyder, 2000; Chiarugi, 2002; Skaper, 2003). It has been reported, however, that ATP but not NAD contents are reduced in the ischemic brain (Paschen et al, 2000). Likewise, we report that procedures able to increase PAR formation in the brain tissue caused ATP but not NAD reduction. Selective ATP depletion may be because of ATP utilization in DNA repair processes and/or PARP-1 activity-dependent mitochondrial impairment (Alano et al, 2004; Hong et al, 2004; Cipriani et al, 2005). Furthermore, evidence that ATP depletion was similar in PARG^+/+₁₁₀ and PARG^−/−₁₁₀ mice suggests that impairment of PAR catabolism does not significantly affect the brain's energy dynamic during hyper-poly(ADP-ribosyl)ation. Under these conditions, it was unknown whether brain synthesizes ADP-ribose. The present finding that ADP-ribose rapidly accumulates in the brain tissue on PARP-1 activation, along with knowledge that it is a precursor of ATP (Oei and Ziegler, 2000), may be of pathophysiologic significance.

It has been reported that PARG inhibitors protect neural cells from oxidative stress, excitotoxicity and brain ischemia (Ying et al, 2001; Lu et al, 2003). Possibly, acute drug actions have a different outcome than congenital PARG suppression. For instance, pharmacological inhibition of PARG leads to increased PARP-1 auto-poly(ADP-ribosyl)ation while PARG^−/−₁₁₀ cells have a reduced PARP-1 automodification (Cortes et al, 2004). This may result in opposing effects on PARP-1 activity and on cell resistance to noxious stimuli. It is also worth noting that PARG inhibitors may block all PARG isoforms, whereas genetic inactivation of a single PARG isoform may have a less pronounced impact on polymer catabolism. It is also worth noting, however, that specificity as well as efficacy of current chemical inhibitors of PARG have been recently challenged (Falsig et al, 2004), thereby indicating that caution should be exercised when interpreting data obtained by pharmacologically targeting PARG activity. Finally, in contrast with our findings, two studies have recently reported the detrimental role of PARG₁₁₀ in the gut (Cuzzocrea et al, 2005) and renal ischemia (Patel et al, 2005). Unfortunately, in these studies it has not been reported whether PAR accumulates in the gut or kidney after ischemia. In the light of the fact that inhibition of PAR neoformation protects from postischemic damage in the gut, kidney, and brain, at present we are unable to explain the apparent opposite role of PARG₁₁₀ in peripheral and brain ischemia. Yet, our result are in keeping with the detrimental effects of parg targeting in Drosophila (Hanai et al, 2004) and mouse embryo (Koh et al, 2004).

In conclusion, our findings emphasize the relevance of PAR catabolism to protein expression profile within the brain and ischemic brain injury. Strategies aimed at preventing deregulation of PAR homeostasis might prove useful for therapeutic purposes.

References

Affar

Germain

Winstall

Vodenicharov

Shah

Salvesen

Poirier

(2001) Caspase-3-mediated processing of poly(ADP-ribose) glycohydrolase during apoptosis. J Biol Chem 276:2935–42

Alano

Ying

Swanson

(2004) Poly(ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD⁺ depletion and mitochondrial permeability transition. J Biol Chem 279:18895–902

Ame

Spenlehauer

de Murcia

(2004) The PARP superfamily. Bioessays 26:882–93

Barone

Feuerstain

(1999) Inflammatory mediators and stroke: novel opportunities for novel therapeutics. J Cereb Blood Flow Metab 19:819–34

Bates

Read

Harrison

Topp

Morrow

Gale

Murdock

Barone

Parsons

Gloger

(2001) Molecular characterization by subtractive hybridization of the Zea Longa model of permanent middle cerebral artery occlusion in the rat. Identification of novel gene expression following experimental ischemia. Mol Brain Res 93:70–80

Bonicalzi

Haince

Droit

Poirier

(2005) Regulation of poly(ADP-ribose) metabolism by poly(-ADP-ribose) glycohydrolase: where and when? Cell Mol Life Sci 62:739–50

Bonicalzi

Vodenicharov

Coulombe

Gagne

Poirier

(2003) Alteration of poly(ADP-ribose) glycohydrolase nucleocytoplasmic shuttling characteristics upon cleavage by apoptotic proteases. Biol Cell 95:635–44

Chang

Jacobson

Mitchinson

(2004) Poly(ADP-ribose) is required for spindle assembly and structure. Nature 432:645–9

Chiarugi

(2002) PARP-1: killer or conspirator. The suicide hypothesis revisited. Trends Pharmacol Sci 23:122–9

10.

Chiarugi

(2005a) Intrinsic mechanisms of poly(ADP-ribose) neurotoxicity: three hypotheses. Neurotoxicology (in press)

11.

Chiarugi

(2005b) Poly(ADP-ribosyl)ation and stroke. Pharmacol Res 52:15–24

12.

Chiarugi

Moskowitz

(2003) Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J Neurochem 85:306–17

13.

Cipriani

Rapizzi

Vannacci

Rizzuto

Moroni

Chiarugi

(2005) Nuclear poly (ADP-ribose) polymerase-1 rapidly triggers mitochondrial dysfunction. J Biol Chem 280:17227–34

14.

Cortes

Tong

Coyle

Meyer-Ficca

Meyer

Petrilli

Herceg

Jacobson

Wang

(2004) Depletion of the 110-kilodalton isoform of poly(ADP-ribose) glycohydrolase increases sensitivity to genotoxic and endotoxic stress in mice. Mol Cell Biol 24:7163–78

15.

Cuzzocrea

Di Paola

Mazzon

Cortes

Genovese

Muia

Zhang

Wang

(2005) PARG activity mediates intestinal injury induced by splanchnic artery occlusion and reperfusion. FASEB J 19:558–66

16.

D'Amours

Desnoyers

Poirier

(1999) Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 342:249–68

17.

Datta

Brunet

Greenberg

(1999) Cellular survival: a play in three Akts. Genes Dev 13:2905–27

18.

Davidovich

Vodenicharov

Affar

Poirier

(2001) Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism. Exp Cell Res 268:7–13

19.

Di Meglio

Denegri

Vallefuoco

Tramontano

Scovassi

Quesada

(2003) Poly(ADPR) polymerase-1 and poly(ADPR) glycohydrolase level and distribution in differentiating rat germinal cells. Mol Cell Biochem 248:85–91

20.

Falsig

Christiansen

Feuerhahn

Burkle

Oei

Keil

Leist

(2004) Poly(ADP-ribose) glycohydrolase as a target for neuroprotective intervention: assessment of currently available pharmacological tools. Eur J Pharmacol 497:7–16

21.

Goto

Xue

Sugo

Sawada

Blizzard

Poitras

Johns

Dawson

Crain

Traistman

Mori

Hurn

(2002) Poly(ADP-ribose) polymerase impairs early and long-term experimental stroke recovery. Stroke 33:1101–6

22.

Hester

Snyder

(2002) Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc Natl Acad Sci 99:3270–5

23.

Snyder

(1999) Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci 69:13978–82

24.

Snyder

(2000) Poly (ADP-ribose) polymerase-1 in the nervous system. Neurobiol Dis 7:225–39

25.

Hagberg

Wilson

Matsushita

Zhu

Lange

Gustavsson

Poitras

Dawson

Northington

Johnston

(2004) PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. J Neurochem 90:1068–75

26.

Hanai

Kanai

Ohashi

Okamoto

Yamada

Takahashi

Miwa

(2004) Loss of poly(ADP-ribose) glycohydrolase causes progressive neurodegeneration in Drosophila melanogaster. Proc Natl Acad Sci USA 101:82–6

27.

Hassa

Hottiger

(2002) The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol Life Sci 59:1534–53

28.

Herceg

Wang

(2001) Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res 477:97–110

29.

Hong

Dawson

(2004) Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci 25:259–64

30.

Iadecola

Alexander

(2001) Cerebral ischemia and inflammation. Curr Opin Neurol 14:89–94

31.

Koh

Lawler

Poitras

Sasaki

Wattler

Nehls

Stoger

Poirier

Dawson

(2004) Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proc Natl Acad Sci USA 101:17699–704

32.

Kraus

Lis

(2003) PARP goes transcription. Cell 113:677–83

33.

Lee

Kim

Yoou

Kim

Roh

Lee

Seo

(2001) Targeted hsp70.1 disruption increases infarction volume after focal cerebral ischemia in mice. Stroke 32:2905–12

34.

Dalkara

Moskowitz

(2003) Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4:399–415

35.

Massuda

Lin

Zhang

(2003) Post-treatment with a novel PARG inhibitor reduces infarct in cerebral ischemia in the rat. Brain Res 978:99–103

36.

McCullough

Zeng

Blizzard

Debchoudhury

Hurn

(2005) Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection. J Cereb Blood Flow Metab 25:502–12

37.

Meyer-Ficca

Meyer

Coyle

Jacobson

(2004) Human poly(ADP-ribose) glycohydrolase is expressed in alternative splice variants yielding isoforms that localize to different cell compartments. Exp Cell Res 297:521–32

38.

Moroni

Meli

Peruginelli

Chiarugi

Cozzi

Picca

Romagnoli

Pellicciari

Pellegrini-Giampietro

(2001) Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia. Cell Death Differ 8:921–32

39.

Oei

Ziegler

(2000) ATP for the DNA ligation step in base excision repair is generated from poly(ADP-ribose). J Biol Chem 275:23234–9

40.

Ohashi

Kanai

Hanai

Uchiumi

Maruta

Tanuma

Miwa

(2003) Subcellular localization of poly(ADP-ribose) glycohydrolase in mammalian cells. Biochem Biophys Res Commun 307:915–21

41.

Panda

Poirier

Kay

(2002) Tej defines a role for poly(ADP-ribosyl)ation in establishing period length of the Arabidopsis circadian oscillator. Dev Cell 3:51–61

42.

Park

Cho

Frys

Racchumi

Zhou

Anrather

Iadecola

(2004) Interaction between inducible nitric oxide synthase and poly(ADP-ribose) polymerase in focal ischemic brain injury. Stroke 35:2896–901

43.

Paschen

Olah

Mies

(2000) Effect of transient focal ischemia of mouse brain on energy state and NAD levels: no evidence that NAD depletion plays a major role in secondary disturbances of energy metabolism. J Neurochem 75:1675–80

44.

Patel

Cortes

Di Poala

Mazzon

Mota-Filipe

Cuzzocrea

Wang

Thiemermann

(2005) Mice lacking the 110-kD isoform of poly(ADP-ribose) glycohydrolase are protected against renal ischemia/reperfusion injury. J Am Soc Nephrol 16:712–9

45.

Rapizzi

Fossati

Moroni

Chiarugi

(2004) Inhibition of poly(ADP-ribose) glycohydrolase by gallotannin selectively up-regulates expression of proinflammatory genes. Mol Pharmacol 66:890–8

46.

Read

Parsons

Harrison

Philpott

Kabnick

O'Brien

Clark

Brawner

Bates

Gloger

Legos

Barone

(2001) Stroke genomics: approaches to identify, validate, and understand ischemic stroke gene expression. J Cereb Blood Flow Metab 21:755–78

47.

Rouleau

Aubin

Poirier

(2004) Poly(ADP-ribosyl)ated chromatin domains: access granted. J Cell Sci 117:815–25

48.

Skaper

(2003) Poly(ADP-ribosyl)ation enzyme-1 as a target for neuroprotection in acute central nervous system injury. Curr Drug Targets CNS Neurol Disord 2:279–91

49.

Smith

(2001) The world according to PARP. Trends Biochem Sci 26:174–9

50.

Stenzel-Poore

Stevens

Simon

(2004) Genomics of preconditioning. Stroke 35:2683–6

51.

Swanson

Sharp

(1994) Infarct measurement methodology. J Cereb Blood Flow Metab 14:697–8

52.

Szabo

Dawson

(1998) Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci 19:287–98

53.

Tsai

Aoki

Maruta

Abe

Sakagami

Hatano

Okuda

Tanuma

(1992) Mouse mammary tumor virus gene expression is suppressed by oligomeric ellagitannins, novel inhibitors of poly(ADP-ribose) glycohydrolase. J Biol Chem 267:14436–42

54.

Tulin

Spradling

(2003) Chromatin loosening by poly(ADP)-ribose polymerase (PARP) at Drosophila puff loci. Science 299:560–2

55.

Ullrich

Diestel

Eyupoglu

Nitsch

(2001) Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat Cell Biol 3:1035–42

56.

Weinstein

Hong

Sharp

(2004) Molecular identification of the ischemic penumbra. Stroke 35:2666–70

57.

Yano

Morioka

Fukunaga

Kawano

Hara

Kai

Hamada

Miyamoto

Ushio

(2001) Activation of Akt/protein kinase B contributes to induction of ischemic tolerance in the CA1 subfield of gerbil hippocampus. J Cereb Blood Flow Metab 21:351–60

58.

Ying

Sevigny

Chen

Swanson

(2001) Poly(ADP-ribose) glycohydrolase mediates oxidative and excitotoxic neuronal death. Proc Natl Acad Sci USA 98:12227–32

59.

Poitras

Coombs

Bowers

Federoff

Poirier

Dawson

(2002) Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297:259–63

60.

Ziegler

Oei

(2001) A cellular survival switch: poly(ADP-ribosyl)ation stimulates DNA repair and silences transcription. Bioessay 23:543–8

61.

Zingarelli

Hake

O'Connor

Denenberg

Wong

Kong

Aronow

(2004) Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1. Am J Physiol Heart Circ Physiol 286:H1408–15

Poly(ADP-ribose) Accumulation and Enhancement of Postischemic Brain Damage in 110-kDa Poly(ADP-ribose) Glycohydrolase Null Mice

Abstract

Keywords

Introduction

Materials and methods

Induction of Distal Middle Cerebral Artery Occlusion and Determination of Infarct Size

Western Blotting and Immunohistochemistry

Semiquantitative Real-Time Polymerase Chain Reaction

Measurement of Nicotinamide Adenine Dinucleotide, Adenosine Triphosphate and Adenosine Diphosphate-Ribose in Mouse Brain Slices

Results

Transcription of Poly(ADP-Ribose) Glycohydrolase Isoforms in Poly(ADP-Ribose) Glycohydrolase110 Wild-Type and Knockout Mouse Brains

Effect of Poly(ADP-Ribose) Glycohydrolase110 Deletion on the Brain Tissue Response to Poly(ADP-Ribose) Polymerase-1 Hyperactivation

Poly(ADP-ribose) Glycohydrolase110 Deletion Increases the Vulnerability to Ischemic Brain Injury

Poly(ADP-Ribose) Glycohydrolase110 Deletion Increases Basal and Ischemia-Induced Cerebral PAR Contents

Effect of Poly(ADP-Ribose) Glycohydrolase110 Deletion on Expression/Activation of Neuroprotective or Neurotoxic Proteins in Control and Ischemic Mouse Brain

Discussion

References

Transcription of Poly(ADP-Ribose) Glycohydrolase Isoforms in Poly(ADP-Ribose) Glycohydrolase₁₁₀ Wild-Type and Knockout Mouse Brains

Effect of Poly(ADP-Ribose) Glycohydrolase₁₁₀ Deletion on the Brain Tissue Response to Poly(ADP-Ribose) Polymerase-1 Hyperactivation

Poly(ADP-ribose) Glycohydrolase₁₁₀ Deletion Increases the Vulnerability to Ischemic Brain Injury

Poly(ADP-Ribose) Glycohydrolase₁₁₀ Deletion Increases Basal and Ischemia-Induced Cerebral PAR Contents

Effect of Poly(ADP-Ribose) Glycohydrolase₁₁₀ Deletion on Expression/Activation of Neuroprotective or Neurotoxic Proteins in Control and Ischemic Mouse Brain